Click here to get full coverage on A Look At Cytokinetics (CYTK) Valuation After Recent Share Price Pullback - simplywall.st

A Look At Cytokinetics (CYTK) Valuation After Recent Share Price Pullback  simplywall.st

A Look At Cytokinetics (CYTK) Valuation After Recent Share Price Pullback - simplywall.st

Click here to get full coverage on Why Cytokinetics (CYTK) Is a Buy - The Villanovan

Why Cytokinetics (CYTK) Is a Buy  The Villanovan

Why Cytokinetics (CYTK) Is a Buy - The Villanovan

Click here to get full coverage on CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans - Yahoo Finance

CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans  Yahoo Finance

CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans - Yahoo Finance

Click here to get full coverage on Monashee Investment Management LLC Buys Shares of 100,000 Cytokinetics, Incorporated $CYTK - MarketBeat

Monashee Investment Management LLC Buys Shares of 100,000 Cytokinetics, Incorporated $CYTK  MarketBeat

Monashee Investment Management LLC Buys Shares of 100,000 Cytokinetics, Incorporated $CYTK - MarketBeat

Click here to get full coverage on CYTK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

CYTK Financials: Income Statement, Balance Sheet & Cash Flow  Stock Titan

CYTK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Click here to get full coverage on Cytokinetics Stock Slides 10% After Q4 Loss Widens: How MYQORZO’s Launch Shape the Outlook - TIKR.com

Cytokinetics Stock Slides 10% After Q4 Loss Widens: How MYQORZO’s Launch Shape the Outlook  TIKR.com

Cytokinetics Stock Slides 10% After Q4 Loss Widens: How MYQORZO’s Launch Shape the Outlook - TIKR.com

Click here to get full coverage on $CYTK stock is down 10% today. Here's what we see in our data. - Quiver Quantitative

$CYTK stock is down 10% today. Here's what we see in our data.  Quiver Quantitative

$CYTK stock is down 10% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Notable Wednesday Option Activity: CYTK, MDB, WBD - Nasdaq

Notable Wednesday Option Activity: CYTK, MDB, WBD  Nasdaq

Notable Wednesday Option Activity: CYTK, MDB, WBD - Nasdaq

Click here to get full coverage on Cytokinetics (CYTK): Leerink Partners Raises Price Target | CYTK Stock News - GuruFocus

Cytokinetics (CYTK): Leerink Partners Raises Price Target | CYTK Stock News  GuruFocus

Cytokinetics (CYTK): Leerink Partners Raises Price Target | CYTK Stock News - GuruFocus

Click here to get full coverage on Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance

Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates  Yahoo Finance

Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance

Click here to get full coverage on New heart drug MYQORZO wins U.S., China, EU nods as launch begins - Stock Titan

New heart drug MYQORZO wins U.S., China, EU nods as launch begins  Stock Titan

New heart drug MYQORZO wins U.S., China, EU nods as launch begins - Stock Titan

Click here to get full coverage on TD Asset Management Inc Raises Stake in Cytokinetics, Incorporated $CYTK - MarketBeat

TD Asset Management Inc Raises Stake in Cytokinetics, Incorporated $CYTK  MarketBeat

TD Asset Management Inc Raises Stake in Cytokinetics, Incorporated $CYTK - MarketBeat

Click here to get full coverage on Decoding Cytokinetics Inc (CYTK): A Strategic SWOT Insight - GuruFocus

Decoding Cytokinetics Inc (CYTK): A Strategic SWOT Insight  GuruFocus

Decoding Cytokinetics Inc (CYTK): A Strategic SWOT Insight - GuruFocus

Click here to get full coverage on Cytokinetics (CYTK) Quarterly Loss Of US$183 Million Reinforces Bearish Profitability Concerns - simplywall.st

Cytokinetics (CYTK) Quarterly Loss Of US$183 Million Reinforces Bearish Profitability Concerns  simplywall.st

Cytokinetics (CYTK) Quarterly Loss Of US$183 Million Reinforces Bearish Profitability Concerns - simplywall.st

Click here to get full coverage on Cytokinetics, Incorporated (CYTK): A Bull Case Theory - Yahoo Finance

Cytokinetics, Incorporated (CYTK): A Bull Case Theory  Yahoo Finance

Cytokinetics, Incorporated (CYTK): A Bull Case Theory - Yahoo Finance

Click here to get full coverage on Cytokinetics (NASDAQ:CYTK) Given New $84.00 Price Target at Leerink Partners - MarketBeat

Cytokinetics (NASDAQ:CYTK) Given New $84.00 Price Target at Leerink Partners  MarketBeat

Cytokinetics (NASDAQ:CYTK) Given New $84.00 Price Target at Leerink Partners - MarketBeat

Click here to get full coverage on Cytokinetics (CYTK): Analyst Jason Butler Raises Price Target to $96 | CYTK Stock News - GuruFocus

Cytokinetics (CYTK): Analyst Jason Butler Raises Price Target to $96 | CYTK Stock News  GuruFocus

Cytokinetics (CYTK): Analyst Jason Butler Raises Price Target to $96 | CYTK Stock News - GuruFocus

Click here to get full coverage on Cytokinetics, Incorporated (CYTK) Poised for Market Share Gain with Myqorzo in Cardiac Myosin Space - Yahoo Finance

Cytokinetics, Incorporated (CYTK) Poised for Market Share Gain with Myqorzo in Cardiac Myosin Space  Yahoo Finance

Cytokinetics, Incorporated (CYTK) Poised for Market Share Gain with Myqorzo in Cardiac Myosin Space - Yahoo Finance

Click here to get full coverage on Envestnet Asset Management Inc. Increases Stock Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat

Envestnet Asset Management Inc. Increases Stock Holdings in Cytokinetics, Incorporated $CYTK  MarketBeat

Envestnet Asset Management Inc. Increases Stock Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat

Click here to get full coverage on Is It Too Late To Reassess Cytokinetics (CYTK) After Its 41% One Year Gain? - simplywall.st

Is It Too Late To Reassess Cytokinetics (CYTK) After Its 41% One Year Gain?  simplywall.st

Is It Too Late To Reassess Cytokinetics (CYTK) After Its 41% One Year Gain? - simplywall.st

Click here to get full coverage on CYTK: MYQORZO approvals drive commercial launch and growth, with robust early U.S. uptake and EU expansion planned - TradingView

CYTK: MYQORZO approvals drive commercial launch and growth, with robust early U.S. uptake and EU expansion planned  TradingView

CYTK: MYQORZO approvals drive commercial launch and growth, with robust early U.S. uptake and EU expansion planned - TradingView

Click here to get full coverage on Cytokinetics (NASDAQ:CYTK) Price Target Raised to $85.00 at Needham & Company LLC - MarketBeat

Cytokinetics (NASDAQ:CYTK) Price Target Raised to $85.00 at Needham & Company LLC  MarketBeat

Cytokinetics (NASDAQ:CYTK) Price Target Raised to $85.00 at Needham & Company LLC - MarketBeat

Click here to get full coverage on Earnings Preview: Cytokinetics (CYTK) Q4 Earnings Expected to Decline - Yahoo Finance

Earnings Preview: Cytokinetics (CYTK) Q4 Earnings Expected to Decline  Yahoo Finance

Earnings Preview: Cytokinetics (CYTK) Q4 Earnings Expected to Decline - Yahoo Finance

Click here to get full coverage on CYTK Sees Positive Analyst Ratings as Needham Raises Price Targe - GuruFocus

CYTK Sees Positive Analyst Ratings as Needham Raises Price Targe  GuruFocus

CYTK Sees Positive Analyst Ratings as Needham Raises Price Targe - GuruFocus

Click here to get full coverage on Cytokinetics (NASDAQ:CYTK) Stock Price Down 7.7% After Earnings Miss - MarketBeat

Cytokinetics (NASDAQ:CYTK) Stock Price Down 7.7% After Earnings Miss  MarketBeat

Cytokinetics (NASDAQ:CYTK) Stock Price Down 7.7% After Earnings Miss - MarketBeat

Click here to get full coverage on Truist Notes Operational Investments For Cytokinetics, Incorporated (CYTK) to Support Short-Term Growth - Finviz

Truist Notes Operational Investments For Cytokinetics, Incorporated (CYTK) to Support Short-Term Growth  Finviz

Truist Notes Operational Investments For Cytokinetics, Incorporated (CYTK) to Support Short-Term Growth - Finviz

Click here to get full coverage on Cytokinetics Inc (CYTK) Q4 2025 Earnings Call Highlights: Strong - GuruFocus

Cytokinetics Inc (CYTK) Q4 2025 Earnings Call Highlights: Strong  GuruFocus

Cytokinetics Inc (CYTK) Q4 2025 Earnings Call Highlights: Strong - GuruFocus

Click here to get full coverage on Cytokinetics, Incorporated (NASDAQ:CYTK) Q4 2025 Earnings Call Transcript - Insider Monkey

Cytokinetics, Incorporated (NASDAQ:CYTK) Q4 2025 Earnings Call Transcript  Insider Monkey

Cytokinetics, Incorporated (NASDAQ:CYTK) Q4 2025 Earnings Call Transcript - Insider Monkey

Click here to get full coverage on Cytokinetics (NASDAQ:CYTK) Given New $96.00 Price Target at Citizens Jmp - MarketBeat

Cytokinetics (NASDAQ:CYTK) Given New $96.00 Price Target at Citizens Jmp  MarketBeat

Cytokinetics (NASDAQ:CYTK) Given New $96.00 Price Target at Citizens Jmp - MarketBeat

Click here to get full coverage on Vanguard Group Inc. Sells 127,043 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat

Vanguard Group Inc. Sells 127,043 Shares of Cytokinetics, Incorporated $CYTK  MarketBeat

Vanguard Group Inc. Sells 127,043 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat

Click here to get full coverage on Cytokinetics (NASDAQ:CYTK) Issues Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat

Cytokinetics (NASDAQ:CYTK) Issues Earnings Results, Misses Estimates By $0.02 EPS  MarketBeat

Cytokinetics (NASDAQ:CYTK) Issues Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat

Click here to get full coverage on Cytokinetics (CYTK) Valuation Check After MYQORZO Approval And Renewed Analyst Bullishness - Yahoo Finance

Cytokinetics (CYTK) Valuation Check After MYQORZO Approval And Renewed Analyst Bullishness  Yahoo Finance

Cytokinetics (CYTK) Valuation Check After MYQORZO Approval And Renewed Analyst Bullishness - Yahoo Finance

Click here to get full coverage on Earnings Flash (CYTK) Cytokinetics Posts Q4 Loss $-1.50, vs. FactSet Est of Loss of $-1.56 - marketscreener.com

Earnings Flash (CYTK) Cytokinetics Posts Q4 Loss $-1.50, vs. FactSet Est of Loss of $-1.56  marketscreener.com

Earnings Flash (CYTK) Cytokinetics Posts Q4 Loss $-1.50, vs. FactSet Est of Loss of $-1.56 - marketscreener.com

Click here to get full coverage on Why Is Cytokinetics (CYTK) Up 10.4% Since Last Earnings Report? - Yahoo Finance

Why Is Cytokinetics (CYTK) Up 10.4% Since Last Earnings Report?  Yahoo Finance

Why Is Cytokinetics (CYTK) Up 10.4% Since Last Earnings Report? - Yahoo Finance

Click here to get full coverage on Is First U.S. MYQORZO Approval Reshaping The Investment Case For Cytokinetics (CYTK)? - Yahoo Finance

Is First U.S. MYQORZO Approval Reshaping The Investment Case For Cytokinetics (CYTK)?  Yahoo Finance

Is First U.S. MYQORZO Approval Reshaping The Investment Case For Cytokinetics (CYTK)? - Yahoo Finance

Click here to get full coverage on Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech Powerhouse with 33% Potential Upside - DirectorsTalk Interviews

Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech Powerhouse with 33% Potential Upside  DirectorsTalk Interviews

Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech Powerhouse with 33% Potential Upside - DirectorsTalk Interviews

Click here to get full coverage on Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update - ChartMill

Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update  ChartMill

Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update - ChartMill

Click here to get full coverage on Cytokinetics (CYTK) Is Up 5.2% After Aficamten Milestones And Probe News Has The Bull Case Changed? - Yahoo Finance

Cytokinetics (CYTK) Is Up 5.2% After Aficamten Milestones And Probe News Has The Bull Case Changed?  Yahoo Finance

Cytokinetics (CYTK) Is Up 5.2% After Aficamten Milestones And Probe News Has The Bull Case Changed? - Yahoo Finance

Click here to get full coverage on Cytokinetics Q4 Earnings Summary & Key Takeaways - Benzinga

Cytokinetics Q4 Earnings Summary & Key Takeaways  Benzinga

Cytokinetics Q4 Earnings Summary & Key Takeaways - Benzinga

Click here to get full coverage on Cytokinetics (CYTK) Valuation Check After Shareholder Investigation Into Aficamten FDA Review Disclosures - Yahoo Finance

Cytokinetics (CYTK) Valuation Check After Shareholder Investigation Into Aficamten FDA Review Disclosures  Yahoo Finance

Cytokinetics (CYTK) Valuation Check After Shareholder Investigation Into Aficamten FDA Review Disclosures - Yahoo Finance

Click here to get full coverage on A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $80 to $107 - 富途牛牛

A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $80 to $107  富途牛牛

A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $80 to $107 - 富途牛牛

Click here to get full coverage on T. Rowe Price (CYTK holder) discloses 14.5% Cytokinetics ownership in 13G/A - Stock Titan

T. Rowe Price (CYTK holder) discloses 14.5% Cytokinetics ownership in 13G/A  Stock Titan

T. Rowe Price (CYTK holder) discloses 14.5% Cytokinetics ownership in 13G/A - Stock Titan

Click here to get full coverage on New MYQORZO drug wins EU nod to treat symptomatic obstructive HCM - Stock Titan

New MYQORZO drug wins EU nod to treat symptomatic obstructive HCM  Stock Titan

New MYQORZO drug wins EU nod to treat symptomatic obstructive HCM - Stock Titan

Click here to get full coverage on Cytokinetics Inc (CYTK) Q3 2025 Earnings Call Highlights: Progress Towards Aficamptin Approval ... - Yahoo Finance

Cytokinetics Inc (CYTK) Q3 2025 Earnings Call Highlights: Progress Towards Aficamptin Approval ...  Yahoo Finance

Cytokinetics Inc (CYTK) Q3 2025 Earnings Call Highlights: Progress Towards Aficamptin Approval ... - Yahoo Finance

Click here to get full coverage on Cytokinetics (CYTK): Exploring Valuation After Recent Share Price Momentum and Growth Narrative - Yahoo Finance

Cytokinetics (CYTK): Exploring Valuation After Recent Share Price Momentum and Growth Narrative  Yahoo Finance

Cytokinetics (CYTK): Exploring Valuation After Recent Share Price Momentum and Growth Narrative - Yahoo Finance

Click here to get full coverage on Do you own shares of CYTK? Robbins LLP Informs Investors of the Cytokinetics, Inc. Class Action Lawsuit - PR Newswire

Do you own shares of CYTK? Robbins LLP Informs Investors of the Cytokinetics, Inc. Class Action Lawsuit  PR Newswire

Do you own shares of CYTK? Robbins LLP Informs Investors of the Cytokinetics, Inc. Class Action Lawsuit - PR Newswire

Click here to get full coverage on Cytokinetics Inc (CYTK) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance

Cytokinetics Inc (CYTK) Q3 2025 Earnings Report Preview: What To Expect  Yahoo Finance

Cytokinetics Inc (CYTK) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance

Click here to get full coverage on CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans - sharewise.com

CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans  sharewise.com

CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans - sharewise.com

Click here to get full coverage on Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO - Nasdaq

Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO  Nasdaq

Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO - Nasdaq

Click here to get full coverage on Why CYTK Faces New Questions on Management Credibility Amid Regulatory Scrutiny and Investor Lawsuits - Yahoo Finance

Why CYTK Faces New Questions on Management Credibility Amid Regulatory Scrutiny and Investor Lawsuits  Yahoo Finance

Why CYTK Faces New Questions on Management Credibility Amid Regulatory Scrutiny and Investor Lawsuits - Yahoo Finance

Click here to get full coverage on Cytokinetics (CYTK) Rockets 40.45% as Aficamten Results Promising - Yahoo Finance

Cytokinetics (CYTK) Rockets 40.45% as Aficamten Results Promising  Yahoo Finance

Cytokinetics (CYTK) Rockets 40.45% as Aficamten Results Promising - Yahoo Finance

Click here to get full coverage on New campaigns give HCM patients, families stronger voices - Stock Titan

New campaigns give HCM patients, families stronger voices  Stock Titan

New campaigns give HCM patients, families stronger voices - Stock Titan

Click here to get full coverage on New heart drug MYQORZO approved to help adults with obstructive HCM symptoms - Stock Titan

New heart drug MYQORZO approved to help adults with obstructive HCM symptoms  Stock Titan

New heart drug MYQORZO approved to help adults with obstructive HCM symptoms - Stock Titan

Click here to get full coverage on Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares - The Motley Fool

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares  The Motley Fool

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares - The Motley Fool

Click here to get full coverage on Cytokinetics (CYTK) Expected to Announce Earnings on Tuesday - MarketBeat

Cytokinetics (CYTK) Expected to Announce Earnings on Tuesday  MarketBeat

Cytokinetics (CYTK) Expected to Announce Earnings on Tuesday - MarketBeat

Click here to get full coverage on Assessing Whether Cytokinetics (CYTK) Looks Undervalued After Recent Share Price Momentum - Yahoo Finance

Assessing Whether Cytokinetics (CYTK) Looks Undervalued After Recent Share Price Momentum  Yahoo Finance

Assessing Whether Cytokinetics (CYTK) Looks Undervalued After Recent Share Price Momentum - Yahoo Finance

Click here to get full coverage on Cytokinetics Inc (CYTK) Q4 2025 Earnings Call Highlights: Strong Financial Position Amid Rising ... By GuruFocus - Investing.com Canada

Cytokinetics Inc (CYTK) Q4 2025 Earnings Call Highlights: Strong Financial Position Amid Rising ... By GuruFocus  Investing.com Canada

Cytokinetics Inc (CYTK) Q4 2025 Earnings Call Highlights: Strong Financial Position Amid Rising ... By GuruFocus - Investing.com Canada

Click here to get full coverage on Cytokinetics wins EU approval for cardiovascular drug Myqorzo - MSN

Cytokinetics wins EU approval for cardiovascular drug Myqorzo  MSN

Cytokinetics wins EU approval for cardiovascular drug Myqorzo - MSN

Click here to get full coverage on B. Riley Securities Reiterates Cytokinetics (CYTK) Buy Recommendation - Nasdaq

B. Riley Securities Reiterates Cytokinetics (CYTK) Buy Recommendation  Nasdaq

B. Riley Securities Reiterates Cytokinetics (CYTK) Buy Recommendation - Nasdaq

Click here to get full coverage on The Bull Case For Cytokinetics (CYTK) Could Change Following MYQORZO Progress And HCM Advocacy Grants - simplywall.st

The Bull Case For Cytokinetics (CYTK) Could Change Following MYQORZO Progress And HCM Advocacy Grants  simplywall.st

The Bull Case For Cytokinetics (CYTK) Could Change Following MYQORZO Progress And HCM Advocacy Grants - simplywall.st

Click here to get full coverage on Cytokinetics (CYTK): Is the Current Market Valuation Overlooking the Company’s Long-Term Potential? - Yahoo Finance

Cytokinetics (CYTK): Is the Current Market Valuation Overlooking the Company’s Long-Term Potential?  Yahoo Finance

Cytokinetics (CYTK): Is the Current Market Valuation Overlooking the Company’s Long-Term Potential? - Yahoo Finance

Click here to get full coverage on Liquidity Mapping Around (CYTK) Price Events - Stock Traders Daily

Liquidity Mapping Around (CYTK) Price Events  Stock Traders Daily

Liquidity Mapping Around (CYTK) Price Events - Stock Traders Daily

Click here to get full coverage on Cytokinetics (CYTK) Price Target Raised by RBC Capital on Februa - GuruFocus

Cytokinetics (CYTK) Price Target Raised by RBC Capital on Februa  GuruFocus

Cytokinetics (CYTK) Price Target Raised by RBC Capital on Februa - GuruFocus

Click here to get full coverage on Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates  Yahoo Finance

Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on Cytokinetics: Small Label Differences With Big Commercial Stakes (CYTK) - Seeking Alpha

Cytokinetics: Small Label Differences With Big Commercial Stakes (CYTK)  Seeking Alpha

Cytokinetics: Small Label Differences With Big Commercial Stakes (CYTK) - Seeking Alpha

Click here to get full coverage on Insider Sale: EVP of $CYTK Sells 1,042 Shares - Quiver Quantitative

Insider Sale: EVP of $CYTK Sells 1,042 Shares  Quiver Quantitative

Insider Sale: EVP of $CYTK Sells 1,042 Shares - Quiver Quantitative

Click here to get full coverage on Cytokinetics Gains EU MYQORZO Approval As Market Weighs Valuation Upside - simplywall.st

Cytokinetics Gains EU MYQORZO Approval As Market Weighs Valuation Upside  simplywall.st

CYTK

Price Chart

Key Statistics

Technicals

About CYTK

Latest News

A Look At Cytokinetics (CYTK) Valuation After Recent Share Price Pullback - simplywall.st

Why Cytokinetics (CYTK) Is a Buy - The Villanovan

CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers